Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people.

Website:
www.oxb.com
Company Type
Twitter Account
@oxfordbiomedica
News Page URL
Click here

Parkinsons Concierge

Who are we?

At Parkinson’s Concierge we want to promote Patient Engagement, Involved,  and have the opportunity to accelerate the desperate need for a Cure.

It is now evident that to find a Cure for Parkinson’s everyone needs to be involved and partnering with each other.

At Parkinson’s Concierge we are becoming a voice for People with Parkinson’s.

We all live with Parkinson's.

We want to be involved in all aspects of finding a cure for Parkinson’s and believe it is the way forward to be the final link between Tech companies/ Pharma/Medical Industry Professionals.

Inclusion is required in the following areas

Involved with the strategic development of patient and professional relationships

Enable us to contribute to funding for clinical research trials for Parkinson’s

We have a particular interest in engaging with early detection/research companies

Connecting and communicating with stakeholders

Identifying key relationships between all business partnerships

We are Advocates of the Parkinson’s Movement

We sit on the Panel of Parkinson’s Steering Committees at various hospitals for research

Inclusion with clinical trials where Patients can be involved with execution through to completion by providing tech data (that is so desperately needed) from the people who live with Parkinson’s

What can we offer you?

Within our team we have people with expertise in the areas of drug development, clinical trial operations, and strategic planning, relationship management, awareness creation, & training

Our biggest USP is of course, we ALL have Parkinson’s

We are 100% committed to devoting the rest of our lives to improving the lives of people affected by Parkinson’s

Our Unique Business Model can be rolled out Worldwide with the right investment and backing

We also have experience working with multiple vendors

We possess strong planning and tracking skills

We are customer focused, well organised, detail oriented

We can demonstrate excellent time, priority, and self-management skills

Strong project-management skills

Effective leadership skills and proven ability to foster team productivity and cohesiveness.

Excellent communication skills with the ability to add value to your organisation from a Patient perspective

We have the proven ability to negotiate and influence others

Scope:

  • Acting as Parkinson’s Advocates
  • Advisors on problems in Parkinson’s
  • Bid writing for funding purposes
  • Design of questionnaires
  • Organising focus groups
  • UX design
  • Report writing
  • Public Speaking
  • Creating Awareness at Corporate Events
  • Partnering with organisations who can make a difference

What type of impact can we make?

Our unique business model offers experience, talents and a perspective which can make a vital contribution to innovative products & research methods that the Medical industry are developing for Parkinson’s. Therefore, we can take part in improving the lives of people everywhere suffering from this incurable disease. We want to be part of the change that is needed in order to accelerate finding a cure.

Let’s help the Medical industry to help us – The People with Parkinson’s

Company Type
Twitter Account
@PC3652
News Page URL
Click here

Pebmond Associates

From drug discovery to commercialisation - we support the full spectrum.

Business Development and Licensing - Need support to acquire, divest or license a product or project? That's what we do. Regulatory Affairs, Pharmacovigilance - If you need support with your regulatory affairs, regulatory strategy or pharmacovigilance needs, we can arrange this through our trusted partner organisation. Wide Network - Projects at initial scientific concepts? Products at commercialisation and reimbursement stage? Our partners will help. Due Diligence and Auditing - Looking for support for due diligence, or auditing of partners? We can arrange all this.

Company Type
Keywords
News Page URL
Click here

Pneumagen

Pneumagen is using its platform technology, GlycoTarge™, to develop glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. 

Pneumagen’s lead product, Neumifil™, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV) and Respiratory Synctial Virus (RSV) infections. When administered intranasally in preclinical models, Neumifil™ has demonstrated prevention, treatment and post-exposure prophylaxis of IFV infection with no observed toxicity. Pneumagen’s mCBM, in development for cancer, isknown as Neumonco™. In vitro data have demonstrated that mCBMs target and enter cancer cells, reducing cell proliferation, migration, metabolism and differentiation. 

Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Please visit www.pneumagen.com for more information.

Company Type
Twitter Account
@PneumagenLtd
News Page URL
Click here

Precision for Medicine

Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.

Contact Precision for Medicine, Oncology and Rare Disease via their website

Company Type
Twitter Account
@Precision4Med
News Page URL
Click here

Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

 

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum is based in Cambridge, UK and listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.

Website:
www.sareum.co.uk
Company Type
Twitter Account
@Sareumplc
News Page URL
Click here

Scendea

Scendea was founded as a result of a management buyout of the product development and regulatory consulting function of a clinical research organisation. Our origin dates back over 20 years, with involvement in over 1,000 development programmes.

Scendea’s expert team delivers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory to successfully guide products from early development to marketing approval. 

A combination of scientific excellence, industry experience, commercial awareness and a collaborative approach allow our expert team to solve complex issues associated with medicinal product development. Scendea has team members based in the UK, Ireland, the Netherlands and the US, who deliver innovative and high-quality solutions aligned to jurisdiction-specific regulatory requirements.

At Scendea we collaborate, innovate, and together with our clients, we succeed.

Company Type
Twitter Account
@scendea
News Page URL
Click here

Sekisui

Sekisui Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years. We continue to invest in new diagnostic products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems. We are a leading provider of rapid tests in the U.S., and high throughput coagulation systems in Japan. We develop, manufacture, and supply over 1.7 billion tests each year to the global healthcare market through direct sales, our commercial distribution networks and our partners.

Company Type
Keywords
Twitter Account
@SekisuiDx
News Page URL
Click here

Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

Company Type
Twitter Account
@SilenceTheraPlc
News Page URL
Click here

Sphere Fluidics

Sphere Fluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.

Specialities
Biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells

Company Type
Twitter Account
@SphereFluidics
News Page URL
Click here